

Contact Person: Ming Yan, MD, Ph.D., Scientific Review Officer, Immunology (IMM), DPPS, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, RM 4205, Bethesda, MD 20892, (301) 594-0343, yanming@mail.nih.gov.

Name of Committee: National Institute of Nursing Research Special Emphasis Panel; Fellowship and Career Development.

Date: February 19, 2021.

Time: 10:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Nursing Research, National Institutes of Health, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Ming Yan, MD, Ph.D., Scientific Review Officer, Immunology (IMM), DPPS, Center for Scientific Review, National Institute of Nursing Research, National Institutes of Health, 6701 Rockledge Drive, RM 4205 Bethesda, MD 20892, (301) 594-0343, yanming@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.361, Nursing Research, National Institutes of Health, HHS)

Dated: January 8, 2021.

Tyeshia Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021-00651 Filed 1-13-21; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke.

Date: April 11-13, 2021.

Time: 3:00 p.m. to 12:00 p.m.

Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators.

Place: Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Lorna W. Role, Ph.D., Scientific Director, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, 35A Convent Drive, MSC 3716, Bethesda, MD 20892, lorna.role@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: January 8, 2021.

Tyeshia M. Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021-00653 Filed 1-13-21; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: Development and Commercialization of CD33-Specific Chimeric Antigen Receptor (CAR) Therapies for CD33-Expressing Malignancies Using Natural Killer Cells (NK Cells) Transduced With Retroviral or Lentiviral Vectors

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Senti Bio ("Senti"), located in South San Francisco, CA.

DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before January 29, 2021 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Jim Knabb, Senior Technology Transfer Manager, NCI Technology Transfer Center at Email: jim.knabb@nih.gov.

SUPPLEMENTARY INFORMATION:

Intellectual Property

E-097-2018-0: Anti-CD33 Chimeric Antigen Receptors for Treatment of Human Acute Myeloid Leukemia

1. US Provisional Patent Application 62/643,015, filed March 14, 2018 (E-097-2018-0-US-01);
2. International Patent Application PCT/US2019/022,309, filed March 14, 2019 (E-097-2018-0-PCT-02)
3. United Arab Emirates Application No: P6001291/2020, filed September 13, 2020 (E-097-2018-0-AE-03)
4. Australia Application No: 2019235926, filed September 2, 2020 (E-097-2018-0-AU-04)
5. Canada Application No: 3,093,567, filed September 9, 2020 (E-097-2018-0-CA-05)
6. China Application No: 201980018105.0, filed September 9, 2020 (E-097-2018-0-CN-06)
7. Eurasia Application No: 202092044, filed September 25, 2020 (E-097-2018-0-EA-07)
8. European Patent Application No: 19714007.2, filed October 14, 2020 (E-097-2018-0-EP-08)
9. Israel Application No: 277078, filed September 1, 2020 (E-097-2018-0-IL-09)
10. India Application No: 202047039152, filed September 10, 2020 (E-097-2018-0-IN-10)
11. South Korea Application No: 2020-7029302, filed October 13, 2020 (E-097-2018-0-KR-11)
12. Mexico Application No: MX/a/2020/009472, filed September 10, 2020 (E-097-2018-0-MX-12)
13. New Zealand Application No: 767782, filed September 13, 2020 (E-097-2018-0-NZ-13)
14. Saudi Arabia Application No: 520420134, filed September 13, 2020 (E-097-2018-0-SA-14)
15. Singapore Application No: 11202008796V, filed September 9, 2020, (E-097-2018-0-SG-15)
16. United States of America Application No: 16/980,205, filed September 11, 2020 (E-097-2018-0-US-16)
17. South Africa Application No: 2020/05571, filed September 8, 2020 (E-097-2018-0-ZA-17)

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide, and the fields of use may be limited to the following:

An exclusive license to:

1. The development of a CD33-specific logic-gated CAR-based